Pictor has with Mobility Health to launch a new antibody test, PictArray SARS-CoV2, following the receipt of a $6.1m investment.
The investment was led by former Morrison & Co CEO Marko Bogoievski and K One W One (K1W1).
The funding round also saw participation from 20 other investors. This brought the overall capital raised by Pictor to $17m.
This financing will be utilised for the development and marketing of the PictArray SARS-CoV2 antibody test, as well as other Pictor鈥檚 in-vitro diagnostics.
PictArray SARS-CoV-2 test is designed for detecting whether a patient has antibodies from a previous SARS-CoV-2 infection (spike protein (SP) and nucleocapsid protein (NP) antibodies) or from vaccination alone (SP antibodies only).
It enables customised Covid-19 assessments and will also indicate whether patients require a Covid-19 booster.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe PictArray test will also indicate whether at-risk patients, who have been vaccinated or got infected, failed to produce a detectable antibody response.
Pictor chief medical officer Tadd Lazarus said: 鈥淭he PictArray SARS-CoV-2 Antibody Test is a high-performance, all-in-one, NP/SP COVID-19 antibody test with serological differentiation.
鈥淭his is the only known test that separately measures antibodies from vaccines and SARS-CoV-2 infection in one test. The separate detection of SP and NP enables more precise clinical intervention.鈥�
The company stated that the antigen test is an advancement with critical applications, including vaccine development, due to its capacity to distinguish between natural and vaccination-based antibodies.
Pictor CEO Howard Moore said: 鈥淲e now have the capital for further market development and launches within the United States, India, Australia, New Zealand, and the EU.鈥�
